My colleague Vikas Dandekar, Pharmasianews bureau chief in India, recently tweeted the following comments from GSK CEO Andrew Witty (at an investor call). "I'm not paying 37 times earnings for an Indian company, I am just not." "We are going to walk away from opportunities that go out of our price range, and where we … Continue reading GSK’s Witty does some tough talk on India M&A
The Public Information Bureau recently issued a release recording Cabinet approval for a national programme to prevent and control cancer, diabetes, cardiovascular risk, and stroke. "The programme will be implemented in 20,000 Sub-Centres and 700 Community Health Centres (CHCs) in 100 Districts across 15 States/Union Territories by promoting healthy lifestyle through massive health education and … Continue reading India to screen 7 crore for diabetes and hypertension
A survey by drug maker sanofi-aventis on diabetes and hypertension prevalance in outpatient settings in ten different states in India revealed some preliminary results based on findings from two states - Delhi and Maharashtra. The study "highlights a high percentage of diabetes and hypertension patients who are suffering from associated co-morbidities such as kidney disease, … Continue reading India’s looming healthcare tab from lifestyle diseases
Children who participated in an allegedly botched Pfizer drug trial in Nigeria in 1996 may still have their day in an American court. The US Supreme Court has refused to block a suit brought against Pfizer by their families. The plaintiffs contend that Pfizer tested its experimental antibiotic Trovan during a meningitis epidemic in Nigeria without following due process … Continue reading Pfizer’s Nigerian nightmare. Or is it the other way around?